Oxford, UK 2/12/18—Absolute Antibody and Kerafast have announced a merger. UK-based Absolute Antibody manufactures and sells more than 3,400 newly engineered–versions of recombinant antibodies. US-based Kerafast supplies over 3,500 reagents, such as antibodies, cell lines and proteins. In partnership with 159 institutes, Kerafast also develops and provides access to investigator-developed materials. “We believe all researchers should have access to recombinant versions of antibodies, especially those developed in academic laboratories that have been the bedrock of so much scientific research,” stated Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Kerafast’s strong existing relationships with research institutions will allow us to advance the creation and availability of recombinant antibodies.” The companies stated that at this time they will retain their individual names and websites.

According to Absolute Antibodies, the company produces its recombinant antibodies using transient transfection, which results in faster production times and higher purity. The company announced last June that sales had grown 195% in the first two quarters, driven by custom services, with a  catalog of 2,500 “off-the-shelf” products. The merger appears to give the company the ability to access researcher-developed content and additional distribution resources.